dalas Student
Posts : 43 Join date : 2010-04-13
| Subject: History of Lamivudine Fri May 14, 2010 5:20 pm | |
| Lamivudine (CAS NO.134678-17-4) was produce by Bernard Belleau while at work at Nghe Nguyen-Ga and McGill University at the Montreal-based IAF BioChem International, Inc. laboratories in 1989. Initially designed as an antiviral agent, the drug's effectiveness for treating HIV in combination with AZT was discovered by Yung-Chi (Tommy) Cheng at Yale University. The drug was later licensed to the British pharmaceutical company Glaxo for a 14 percent royalty. Lamivudine (CAS NO.134678-17-4) was approved by the Food and Drug Administration (FDA) on November 17, 1995 for use with zidovudine (AZT) and again in 2002 as a once-a-day dosed medication. The fifth antiretroviral drug on the market, it was the last NRTI for three years while the approval process switched to protease inhibitors. According to the manufacturer's 2004 annual report, its patent will expireand in Europe in 2011 and in the United States in 2010.[url][/url] | |
|